ClinicalTrials.Veeva

Menu

Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis

G

Goupe d'Etudes et de Recherche Clinique En Rhumatologie

Status and phase

Unknown
Phase 4

Conditions

Arthritis
Rheumatoid Arthritis

Treatments

Drug: Methotrexate
Drug: Adalimumab

Study type

Interventional

Funder types

Other

Identifiers

NCT00291915
GUEPARD-GERCER 2122

Details and patient eligibility

About

Evaluation of two treatment modalities in early potentially severe early arthritis ( Methotrexate alone or in combination with adalimumab)

Full description

Patients: early ( less than 6 months), active ( DAS>5.2),potentially severe ( Leiden score>6) Study design:12 months, prospective , randomized, open Study treatments: Methotrexate at a weekly dose of 0.3mg/kilo alone or in combination with adalimumab 40 mg every the other week Outcome measures: DAS over the 12 months

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Early Active Potentially severe arthritis

Exclusion criteria

  • contra indication of methotrexate or anti TNF

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Central trial contact

Martin SOUBRIER, MD; Maxime r DOUGADOS, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems